6 recruiting, 3 completed, 2 active not recruiting, 2 terminated. 10 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 3, Recruiting 3, Terminated 2, Unknown 2 |
| Phase 1 | 7 | Recruiting 3, Active not recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Malignant Peripheral Nerve Sheath Tumors: new trials by email Literature Review of Malignant Peripheral Nerve Sheath Tumors trials Research Report on Malignant Peripheral Nerve Sheath Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 1 / Phase 2 | Recruiting | Ankit Mangla, MD | 17 | 2026-08-01 | 2026-08-11 |
| Neurofibromatosis Type 1 Tumor Early Detection Study Liquid biopsy for MPNST development - Neurofibromatosis Type 1, Neurofibromatosis 1 | Enrolling by invitation | David Miller | 1000 | 2024-08-07 | 2026-08-31 | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors Selinexor - Wilms Tumor, Rhabdoid Tumor | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2023-08-01 | 2026-10-23 |
| B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Fludarabine, Cyclophosphamide, MESNA - Pediatric Solid Tumor, Osteosarcoma | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 48 | 2022-07-06 | 2026-05-19 |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion MRTX1719 - Mesothelioma, Non Small Cell Lung Cancer | Phase 1 | Recruiting | Bristol-Myers Squibb | 336 | 2022-06-09 | 2026-09-02 |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Selinexor, Ixazomib - Liposarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 1 | Withdrawn | Matthew Ingham | 2020-11-01 | 2020-11-27 | |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab - Pediatric Solid Tumor, Germ Cell Tumor | Phase 1 | Active not recruiting | Seattle Children's Hospital | 68 | 2020-07-13 | 2026-04-28 |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Selumetinib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 21 | 2019-10-02 | 2026-05-27 |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG - Pediatric Solid Tumor, Germ Cell Tumor | Phase 1 | Active not recruiting | Seattle Children's Hospital | 44 | 2019-06-18 | 2026-10-08 |
| Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Hypofractionated radiotherapy, Hyperthermia - Sarcoma, Alveolar Soft Part Sarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 30 | 2018-06-01 | 2021-02-01 |
| Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors Malignant Peripheral Nerve Sheath Tumors | Recruiting | Washington University School of Medicine | 1050 | 2017-04-28 | 2026-03-09 | |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy - Sarcoma, Fibrosarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 46 | 2017-02-11 | 2021-01-22 |
| PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors PLX3397, sirolimus - Sarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 1 / Phase 2 | Terminated | Gulam Manji | 39 | 2015-11-04 | 2025-03-21 |
| SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors everolimus, bevacizumab - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 25 | 2012-09-01 | 2019-03-06 |
| Trial of Dasatinib in Advanced Sarcomas Dasatinib - Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 366 | 2007-05-01 | 2018-11-23 |
| Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors imatinib mesylate - Malignant Peripheral Nerve Sheath Tumors | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 11 | 2006-05-01 | 2012-08-07 |
Neurofibrosarcoma (17) · Sarcoma (10) · Sarcoma, Ewing (5) · Sarcoma, Synovial (5) · Desmoplastic Small Round Cell Tumor (4) · Liposarcoma (4) · Rhabdoid Tumor (4) · Rhabdomyosarcoma (4) · Sarcoma, Clear Cell (4) · Wilms Tumor (4) · Carcinoma (3) · Fibrosarcoma (3) · Hepatoblastoma (3) · Histiocytoma, Malignant Fibrous (3) · Leiomyosarcoma (3)
Neoplasms (17) · Neoplasms by Histologic Type (17) · Neoplasms, Connective Tissue (17) · Neoplasms, Connective and Soft Tissue (17) · Neoplasms, Fibrous Tissue (17) · Neoplasms, Nerve Tissue (17) · Nervous System Diseases (17) · Nervous System Neoplasms (17) · Neurofibroma (17) · Neuromuscular Diseases (17) · Peripheral Nervous System Diseases (17) · Peripheral Nervous System Neoplasms (17) · Nerve Sheath Neoplasms (16) · Fibrosarcoma (14) · Neoplasms, Muscle Tissue (8)
Radiation Dose Hypofractionation (2) · Sirolimus (2) · selinexor (2) · AZD 6244 (1) · Bevacizumab (1) · Cyclophosphamide (1) · Dasatinib (1) · Diathermy (1) · Doxorubicin (1) · Everolimus (1) · Ifosfamide (1) · Imatinib Mesylate (1) · Injections (1) · Liquid Biopsy (1) · Mesna (1)
Sarcoma Alliance for Research through Collaboration (3) · Maria Sklodowska-Curie National Research Institute of Oncology (2) · Seattle Children's Hospital (2) · Ankit Mangla, MD (1) · Bristol-Myers Squibb (1) · David Miller (1) · Gulam Manji (1) · HRYZ Biotech Co. (1) · Matthew Ingham (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · St. Jude Children's Research Hospital (1) · Washington University School of Medicine (1)
United States (13) · Poland (2) · Canada (1) · China (1) · Germany (1) · India (1) · Japan (1) · United Kingdom (1)
AeRang Kim, MD, PhD (1) · Angela Hirbe, M.D., Ph.D. (1) · Ankit Mangla, MD (1) · Brigitte C. Widemann, MD (1) · Brigitte Widemann, MD (1) · Catherine Albert, MD (1) · Chris DeRenzo, MD (1) · David T Miller, MD, PhD (1) · Gulam A. Manji, MD (1) · Katie Albert, MD (1) · Matthew Ingham, MD (1) · Michael Ortiz, MD (1)